Psyence Biomedical Agrees To Make Cash Investment Of Up To $5M In Psyence Labs
Transactions include an investment of up to US$5 million in PsyLabs and an approximately US$9 million value-matched share exchangeHighlightsThe Company is actively advancing plans for a potential ibogaine clinical trial
Psyence Biomedical is putting up to $5 million into its sister company Psyence Labs. This shows the company believes in its work testing a medicine called ibogaine.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.